Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$2.14
+0.5%
$1.80
$0.60
$3.08
$174.75M1.4393,997 shs141,734 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.38
+3.1%
$12.67
$6.12
$27.38
$155.86M0.43157,248 shs206,585 shs
Scilex Holding Company stock logo
SCLX
Scilex
$6.32
-2.2%
$5.29
$3.60
$73.50
$43.94M1.1968,387 shs89,431 shs
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
$1.48
$1.50
$0.63
$1.91
$172.94M-0.05474,959 shs106,384 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
0.00%-4.48%-14.46%+122.87%+23.84%
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%-4.11%-3.38%-15.72%+96.72%
Scilex Holding Company stock logo
SCLX
Scilex
0.00%+7.67%+34.02%-2.08%-90.49%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
0.00%-3.90%-4.52%+84.98%+83.17%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
2.8656 of 5 stars
3.73.00.00.02.41.70.6
Lifevantage Corporation stock logo
LFVN
Lifevantage
4.3326 of 5 stars
3.50.01.72.73.82.51.3
Scilex Holding Company stock logo
SCLX
Scilex
2.5688 of 5 stars
3.33.00.00.02.71.70.6
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
1.3575 of 5 stars
0.05.00.00.03.11.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
3.33
Buy$6.00180.37% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50146.37% Upside
Scilex Holding Company stock logo
SCLX
Scilex
2.50
Moderate Buy$455.007,099.37% Upside
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SCLX, TLSA, IMAB, and LFVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
7/9/2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
6/27/2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$4.00 ➝ $5.00
(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$3.89M44.92N/AN/A$2.47 per share0.87
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.78$0.91 per share13.62$2.05 per share6.04
Scilex Holding Company stock logo
SCLX
Scilex
$50.71M0.87N/AN/A($27.68) per share-0.23
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/AN/A$0.04 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
-$22.23MN/A0.00N/AN/AN/A-19.81%-18.63%8/27/2025 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6917.94N/A4.12%34.67%15.24%8/27/2025 (Estimated)
Scilex Holding Company stock logo
SCLX
Scilex
-$72.81M-$29.02N/AN/AN/A-146.93%N/A-82.65%8/12/2025 (Estimated)
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
-$11.86MN/A0.00N/AN/AN/AN/A8/5/2025 (Estimated)

Latest SCLX, TLSA, IMAB, and LFVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.45%N/A26.09%3 Years
Scilex Holding Company stock logo
SCLX
Scilex
N/AN/AN/AN/AN/A
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/AN/AN/A

Latest SCLX, TLSA, IMAB, and LFVN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/A
22.35
22.35
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
Scilex Holding Company stock logo
SCLX
Scilex
N/A
0.10
0.09
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/A
1.02
1.02

Institutional Ownership

CompanyInstitutional Ownership
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38.38%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Scilex Holding Company stock logo
SCLX
Scilex
69.67%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/A

Insider Ownership

CompanyInsider Ownership
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
22.10%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
Scilex Holding Company stock logo
SCLX
Scilex
7.94%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
39.82%
CompanyEmployeesShares OutstandingFree FloatOptionable
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38081.66 million63.61 millionOptionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
Scilex Holding Company stock logo
SCLX
Scilex
806.95 million6.40 millionOptionable
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
8116.85 million70.32 millionOptionable

Recent News About These Companies

Tiziana Life Sciences Ltd (TLSA) - Yahoo Finance
Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

I-Mab stock logo

I-Mab NASDAQ:IMAB

$2.14 +0.01 (+0.47%)
Closing price 04:00 PM Eastern
Extended Trading
$2.15 +0.01 (+0.47%)
As of 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$12.38 +0.37 (+3.08%)
Closing price 04:00 PM Eastern
Extended Trading
$12.36 -0.02 (-0.12%)
As of 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Scilex stock logo

Scilex NASDAQ:SCLX

$6.32 -0.14 (-2.17%)
Closing price 04:00 PM Eastern
Extended Trading
$6.32 0.00 (-0.08%)
As of 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

Tiziana Life Sciences stock logo

Tiziana Life Sciences NASDAQ:TLSA

$1.48 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.52 +0.04 (+3.04%)
As of 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.